NEXTSTELLIS demonstrated efficacy and safety in a robust clinical trial program.
The Phase III patient population included women 16 to 50 years of age and a high-BMI cohort (22% of patients had BMI 30-35 kg/m2).1-3
In 2 Phase II safety studies, NEXTSTELLIS was studied head-to-head against 2 standard-of-care COCs*:
*Both Phase II studies included Yaz® (EE/DRSP) as a comparator; only 1 (C201) included Nordette® (EE/LNG)
**European trade name is Melleva®6